• Product name
    Anti-XIAP (phospho S87) antibody [EPR572(N)]
    See all XIAP primary antibodies
  • Description
    Rabbit monoclonal [EPR572(N)] to XIAP (phospho S87)
  • Host species
  • Tested applications
    Suitable for: WBmore details
    Unsuitable for: Flow Cyt,ICC/IF,IHC-P or IP
  • Species reactivity
    Reacts with: Human
    Does not react with: Mouse, Rat
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) within Human XIAP aa 50-150 (phospho S87) (Cysteine residue). The exact sequence is proprietary.
    Database link: P98170

  • Positive control
    • Okadaic acid and Calyculin A treated Hela cells
  • General notes



    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab175935 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/5000. Predicted molecular weight: 56 kDa.
  • Application notes
    Is unsuitable for Flow Cyt,ICC/IF,IHC-P or IP.
  • Target

    • Function
      Apoptotic suppressor. Has E3 ubiquitin-protein ligase activity. Mediates the proteasomal degradation of target proteins, such as caspase-3, SMAC or AIFM1. Inhibitor of caspase-3, -7 and -9. Mediates activation of MAP3K7/TAK1, leading to the activation of NF-kappa-B.
    • Tissue specificity
      Ubiquitous, except peripheral blood leukocytes.
    • Involvement in disease
      Defects in XIAP are the cause of lymphoproliferative syndrome X-linked type 2 (XLP2) [MIM:300635]. XLP is a rare immunodeficiency characterized by extreme susceptibility to infection with Epstein-Barr virus (EBV). Symptoms include severe or fatal mononucleosis, acquired hypogammaglobulinemia, pancytopenia and malignant lymphoma.
    • Sequence similarities
      Belongs to the IAP family.
      Contains 3 BIR repeats.
      Contains 1 RING-type zinc finger.
    • Domain
      The first BIR domain is involved in interaction with TAB1/MAP3K7IP1 and is important for dimerization. The second BIR domain is sufficient to inhibit caspase-3 and caspase-7, while the third BIR is involved in caspase-9 inhibition. The interactions with SMAC and PRSS25 are mediated by the second and third BIR domains.
    • Post-translational
      Ubiquitinated and degraded by the proteasome in apoptotic cells.
      Phosphorylation by PKB/AKT protects XIAP against ubiquitination and protects the protein against proteasomal degradation.
    • Cellular localization
    • Information by UniProt
    • Database links
    • Alternative names
      • AP 13 antibody
      • API3 antibody
      • Apoptosis Inhibitor 3 antibody
      • Baculoviral IAP repeat containing 4 antibody
      • Baculoviral IAP Repeat Containing Protein 4 antibody
      • Baculoviral IAP repeat-containing protein 4 antibody
      • BIRC 4 antibody
      • BIRC4 antibody
      • E3 ubiquitin-protein ligase XIAP antibody
      • hIAP-3 antibody
      • hIAP3 antibody
      • HILP antibody
      • IAP 3 antibody
      • IAP like protein antibody
      • IAP-3 antibody
      • IAP-like protein antibody
      • IAP3 antibody
      • ILP 1 antibody
      • ILP antibody
      • ILP1 antibody
      • Inhibitor of apoptosis protein 3 antibody
      • Inhibitor of Apoptosis X Linked antibody
      • Mammalian IAP Homologue A antibody
      • MIHA antibody
      • X linked IAP antibody
      • X linked inhibitor of apoptosis antibody
      • X linked inhibitor of apoptosis E3 ubiquitin protein ligase antibody
      • X linked inhibitor of apoptosis protein antibody
      • X-linked IAP antibody
      • X-linked inhibitor of apoptosis protein antibody
      • Xiap antibody
      • XIAP_HUMAN antibody
      • XLP2 antibody
      see all


    • All lanes : Anti-XIAP (phospho S87) antibody [EPR572(N)] (ab175935) at 1/1000 dilution

      Lane 1 : Hela cell lysate
      Lane 2 : Hela cell lysate treated with Okadaic acid and Calyculin A

      Lysates/proteins at 10 µg per lane.

      Predicted band size: 56 kDa


    This product has been referenced in:
    • Mejia C  et al. Decreased activation of placental mTOR family members is associated with the induction of intrauterine growth restriction by secondhand smoke in the mouse. Cell Tissue Res N/A:N/A (2016). Read more (PubMed: 27613305) »
    See 1 Publication for this product

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab175935.
    Please use the links above to contact us or submit feedback about this product.


    Sign up